文献速递白血病

博纳吐单抗治疗香港儿童急性淋巴细胞白血病的成本效果分析

Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost-effectiveness analysis.
PubMed 文献 · Br J Haematol · 2026-05-27

研究从香港公共医疗提供者视角构建10年Markov模型,模拟新诊断标危B细胞急性淋巴细胞白血病患儿在平均和高复发风险下的结局。比较博纳吐单抗联合化疗一线、二线及单纯化疗三种策略,结果显示一线联合方案在两种风险组中均具成本效果。

要点

  • 博纳吐单抗一线联合化疗在平均和高复发风险组均低于支付意愿阈值。
  • 二线博纳吐单抗联合化疗的ICER低于一线方案。
  • 概率敏感性分析中一线方案在多数模拟中为首选。

核心结论

  • 在新诊断标危B细胞急性淋巴细胞白血病患儿中,一线加用博纳吐单抗看来具有成本效果。

研究设计与样本

  • 从香港公共医疗提供者视角构建10年Markov模型,模拟新诊断标危B细胞ALL患儿在平均和高复发风险下的结局。
  • 评估三种策略:博纳吐单抗联合化疗一线、博纳吐单抗联合化疗二线(一线化疗失败后)、单纯化疗。

主要发现

  • 博纳吐单抗二线治疗的ICER在高和平均复发风险组分别为10 534和12 375美元/QALY。
  • 博纳吐单抗一线治疗的ICER在高和平均复发风险组分别为50 312和54 799美元/QALY。
  • 上述ICER均低于支付意愿阈值162 721美元/QALY。
  • 概率敏感性分析中,一线组在高和平均复发风险组分别于71.4%和90.3%的模拟中为首选。

关键数值与推荐

  • 支付意愿阈值为162 721美元/QALY。
  • 单因素敏感性分析显示,博纳吐单抗一线治疗的指数生存率和博纳吐单抗药物成本为影响因素。

临床怎么用

  • 对于新诊断标危B细胞ALL患儿,可考虑将博纳吐单抗加入一线治疗以改善成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To assess the cost-effectiveness of blinatumomab plus chemotherapy for paediatric patients from Hong Kong public healthcare provider's perspective, a 10-year Markov model was designed to simulate outcomes in paediatric patients with newly diagnosed standard-risk B-cell ALL at: (1) average risk and (2) high risk of relapse. Three treatment strategies were evaluated: (1) blinatumomab plus chemotherapy as first-line therapy; (2) blinatumomab plus chemotherapy as second-line therapy for patients who failed first-line chemotherapy; (3) chemotherapy alone. Model outcomes included direct medical cost, life-year gained (LYG), quality-adjusted life-year (QALY) gained and incremental cost-effectiveness ratio (ICER). Comparing to the next less costly strategy, the ICERs of blinatumomab second-line therapy (10 534 and 12 375 USD/QALY) and blinatumomab first-line therapy (50 312 and 54 799 USD/QALY) were below the willingness-to-pay threshold (162 721 USD/QALY) for high and average risk of relapse groups respectively. One-way sensitivity analysis found that exponential rates of survival with blinatumomab as first-line and blinatumomab drug cost were influential factors. In probabilistic sensitivity analysis, blinatumomab first-line group was the preferred option in 71.4% and 90.3% of simulations in the high and average risk of relapse groups, correspondingly. In conclusion, adding blinatumomab to first-line therapy appears to be cost-effective for paediatric patients with newly diagnosed standard-risk B-cell ALL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rui M, Cheung YT, Zhang H, et al. Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost-effectiveness analysis. Br J Haematol. 2026. PMID: 42203433. doi:10.1111/bjh.70582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。